This is an investigational study of a drug named Reprotrectinib that will be given to patients with advanced solid tumors with ALK, ROS1, or NTRK1-3 rearrangements. Repotrectinib will provide opportunities in clinic to stop the abnormal cell signaling of ALK/ROS1/TRKs in solid malignancies, and overcome your body’s natural resistance to treatment of advanced solid tumors harboring ALK, ROS1, or NTRK1-3 rearrangements.
This is a trial investigating a drug called reprotrectinib to be administered to patients with advanced solid tumors with ALK, ROS1 or NTRK1-3 rearrangements. Repotrectinib will provide opportunities in the clinic to stop aberrant cell signaling of ALK/ROS1/TRKs in solid malignancies and overcome the body's natural resistance to treatment of advanced solid tumors harboring ALK, ROS1 or NTRK1-3 rearrangements.
